Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma
-
O'Brien, Susan (University of California)
;
Hillmen, Peter (St. James University Hospital) ;
Coutre, Steven E (Stanford University School of Medicine) ;
Barr, Paul M (University of Rochester Cancer Center) ;
Fraser, Graeme (McMaster University (Canadà)) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Burger, Jan A. (University of Texas MD Anderson Cancer Center) ;
Dilhuydy, Marie-Sarah (Centre Hospitalier Universitaire Hopitaux de Bordeaux) ;
Hess, Georg (Universitats Medizin Mainz) ;
Moreno Atanasio, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Cramer, Paula (University of Cologne) ;
Liu, Emily (Pharmacyclics LLC. an AbbVie Company) ;
Chang, Stephen (Pharmacyclics LLC. an AbbVie Company) ;
Vermeulen, Jessica (Janssen Research & Development) ;
Styles, Lori (Pharmacyclics LLC. an AbbVie Company) ;
Howes, Angela (Janssen Research & Development) ;
James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ;
Patel, Kalpesh (Janssen Pharmaceuticals. Inc) ;
Graef, Thorsten (Pharmacyclics LLC. an AbbVie Company) ;
Valentino, Rudolph (Pharmacyclics LLC. an AbbVie Company) ;
Universitat Autònoma de Barcelona
Subscribe to this discussion. You will then receive all new comments by email.
guest ::
